DDR1 and cancer: Additionally, the downstream signaling of DDR1, as evidenced by reduced pAKT levels, was significantly decreased in the NSC632839-treated group (Fig. S6C), further highlighting its potential as a therapeutic strategy for DDR1-positive cancers.